Prasinezumab
- Generic Name
- Prasinezumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1960462-19-4
- Unique Ingredient Identifier
- P3Z0Z3P1ZI
- Background
Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 586
- Registration Number
- NCT04777331
- Locations
- 🇵🇱
Nmedis sp. z o.o., Rzeszów, Poland
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath